Anthera Pharmaceuticals Inc
DelistedCIK 1316175fmd_1CWMXQ03KNNMKTTG989TS6NVYFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Mar 31, 2018, 36 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 3 | 0 | – |
| Research and development | – | 8 | 29 | 85 | 49 | 22 | 22 | 33 | 47 | 29 |
| Total operating expenses | – | 12 | 36 | 93 | 56 | 28 | 28 | 38 | 57 | 36 |
| Operating income | – | (12) | (36) | (93) | (56) | (28) | (28) | (35) | (57) | (36) |
| Interest expense | – | – | 1 | 3 | 3 | 3 | 1 | – | – | – |
| Interest and investment income | – | (0) | (0) | 1 | (0) | (0) | (0) | – | – | – |
| Other non-operating income (expense) | – | (0) | (5) | (6) | 11 | (3) | (1) | 0 | 2 | 10 |
| Net income | (18) | (12) | (47) | (99) | (45) | (31) | (30) | (35) | (56) | (27) |
| Net income to common shareholders | (18) | (12) | (40) | (99) | (45) | (31) | (30) | (35) | (66) | (29) |